Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $196 from $194 and keeps an Overweight rating on the shares, noting that Auvelity Q3 sales were about 6% above consensus expectations. After updating the firm’s model for the quarter, the firm slightly increased FY25 estimates for Auvelity and Sunosi given Q3 beats, the analyst noted.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $178 from $176 at BofA
- Axsome Therapeutics price target lowered to $157 from $163 at Wells Fargo
- Axsome Therapeutics Reports Strong Q3 2025 Growth
- Axsome Therapeutics’ Strong Market Position and Growth Potential Highlighted by Impressive Auvelity Performance and Strategic Expansion
- Axsome Therapeutics files automatic mixed securities shelf